China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
February 11 2010 - 4:00PM
PR Newswire (US)
HONG KONG, Feb. 11 /PRNewswire-Asia-FirstCall/ -- China Cord Blood
Corporation ("CCBC" or "the Company") (NYSE:CO), China's leading
provider of cord blood collection, laboratory testing,
hematopoietic stem cell processing, and stem cell storage services,
today announced that the Securities and Exchange Commission ("SEC")
declared the Company's registration statement effective on February
9, 2010. The registration statement relates to the ordinary shares
underlying warrants and certain other securities issued in
connection with the initial public offering of Pantheon China
Acquisition Corp. As a result of the effectiveness, holders of
public warrants issued and outstanding may now exercise them and
receive ordinary shares upon the payment of the related exercise
price. If you have any questions regarding exercise procedures,
please call your broker or Continental Stock Transfer & Trust
at 212.509.4000 ext. 541. About China Cord Blood Corporation China
Cord Blood Corporation is the first and the largest cord blood
banking operator in China in terms of geographical coverage and is
the only cord blood bank operator with more than one license (i.e.,
Beijing and Guangdong). Under the current PRC government
regulations, only one licensed cord blood bank operator is
permitted to operate in each licensed region and only six licenses
have been issued as of today. China Cord Blood Corporation provides
cord blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services. For more information
about China Cord Blood Corporation, please visit:
http://www.chinacordbloodcorp.com/ . For more information, please
contact: China Cord Blood Corporation Ms. Joeling Law Phone:
+852-3605-8180 Email: ICR, Inc. In the United States: Ashley M.
Ammon or Christine Duan Phone: +1-646-277-1200 In China: Wei-Jung
Yang Phone: +86-10-6599-7968 DATASOURCE: China Cord Blood
Corporation CONTACT: Investor & Media Relations, Ms. Joeling
Law of China Cord Blood Corporation, +852-3605-8180, ; or Ashley M.
Ammon or Christine Duan (United States), +1-646-277-1200, or
Wei-Jung Yang (China), +86-10-6599-7968, all of Integrated
Corporate Relations, Inc., for China Cord Blood Corporation
Copyright